Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
566 Results for "
integrin alphaIIbbeta3
" in MedChemExpress (MCE) Product Catalog:
Products (566)
566 Results for "integrin alphaIIbbeta3" in MCE Product Catalog:
Art. -Nr.: HY-184576B
Target:
Forschungsgebiete:
DOPE-PEG3400-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DOPE-PEG3400-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-184576C
Target:
Forschungsgebiete:
DOPE-PEG5000-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DOPE-PEG5000-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-184577
Target:
Forschungsgebiete:
DMG-PEG1000-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DMG-PEG1000-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-184577A
Target:
Forschungsgebiete:
DMG-PEG2000-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DMG-PEG2000-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-184577B
Target:
Forschungsgebiete:
DMG-PEG3400-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DMG-PEG3400-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-184577C
Target:
Forschungsgebiete:
DMG-PEG5000-iRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and iRGD peptide (HY-P0122) as the terminal targeting/functional ligand. DMG-PEG5000-iRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against sequential binding to αv integrins on tumor vasculature → neuropilin-1 (NRP1) in tumor tissue.
Art. -Nr.: HY-P2452
CAS. Nr.: 1217344-74-5
Target:
Forschungsgebiete:
Vitronectin (367-378) corresponds to the 367-378 residue fragment of Vitronectin and is a heparin/glycosaminoglycan-binding peptide. Vitronectin (367-378) acts on cell surface glycosaminoglycans and does not directly bind integrins. Vitronectin (367-378) supports pluripotent stem cell adhesion, proliferation, long-term self-renewal, pluripotency markers, normal karyotype, and undifferentiated culture. Vitronectin (367-378) facilitates the differentiation of human pluripotent stem cells into definitive endoderm and mesoderm . Vitronectin (367-378) can be used in research related to stem cell fate regulation [3].
Art. -Nr.: HY-P3448S1
Synonyms: CEND-1-13C2,15N; iRGD-13C2,15N; LSTA1-13C2,15N
Forschungsgebiete:
Art. -Nr.: HY-P4998
CAS. Nr.: 92899-39-3
Target:
Forschungsgebiete:
Chemotactic Domain of Elastin is an elastin-derived chemotactic hexapeptide that interacts with Galectin-3, integrin αvβ3, and elastin-binding protein (EBP) and promotes cell chemotaxis and migration. Chemotactic Domain of Elastin promotes melanoma cell migration by regulating invasion-related molecules such as CXCR-4/CXCL-12, MMP-2/MMP-3, cell adhesion molecules, and VEGF-C. Chemotactic Domain of Elastin is used for research on elastin-derived peptide signaling and tumor cell migration and invasion [3] .
Art. -Nr.: HY-W654264
Synonyms: 2MBC chloride
Target:
Forschungsgebiete:
KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma .
Art. -Nr.: HY-D2062
CAS. Nr.: 1448146-89-1
Art. -Nr.: HY-P3448S
Synonyms: CEND-1-13C6,15N2; iRGD-13C6,15N2; LSTA1-13C6,15N2
Forschungsgebiete:
Art. -Nr.: HY-15589R
CAS. Nr.: 885101-89-3
Forschungsgebiete:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities [3] .
Art. -Nr.: HY-15701R
CAS. Nr.: 344897-95-6
Target:
Forschungsgebiete:
Leukadherin-1 (Standard) is the analytical standard of Leukadherin-1. This product is intended for research and analytical applications. Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling [3].
Art. -Nr.: HY-184578
Target:
Forschungsgebiete:
DOPE-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Art. -Nr.: HY-184578A
Target:
Forschungsgebiete:
DOPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Art. -Nr.: HY-184578B
Target:
Forschungsgebiete:
DOPE-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Art. -Nr.: HY-184578C
Target:
Forschungsgebiete:
DOPE-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Art. -Nr.: HY-184579
Target:
Forschungsgebiete:
DMG-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
